Pharmacy benefit managers inflated drug prices by $7.3B

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of certain drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in many prescription drug transa
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
Pharmacy benefit managers marked up drug prices by $7.3B, new reports finds
A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of prescription drugs.
FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain
Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments
MedCity News9h
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Lawmakers urge FTC to release newest report on pharmacy benefit managers
A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an ...
policymed.com1d
Second Federal Trade Commission Report on Pharmacy Benefit Managers (PBM’s) Focuses on Specialty Generics
The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...